Monday, February 22, 2021

Stock Market Analysis : Nifty below 15000 mark with Amid Volatility

Stock Market Analysis : Nifty below 15000 mark with Amid Volatility

The Indian markets slid in the early deals of Monday's volatile session, with public sector banks being the top drags. Markets had registered sharp gains post the Union Budget, but last week profit-taking was witnessed. Markets might witness volatile trade this week amid monthly derivatives expiry. 
At 10:10 AM, the front line S&P BSE Sensex was trading at 50,582, down 316 points or 0.62%. Market breadth is flat and out of a total of 2,456 shares traded on the Bombay Stock Exchange,1,181 advanced while 1,144 declined and 131 remained unchanged. The broader Nifty 50 was at 14,902, levels, down 79 points or 0.50%. 

The Nifty sectoral indices, barring the Nifty Metal index, were painted red. In the broader markets, the S&P BSE Midcap and Small cap indices were up 0.13% and 0.3%, respectively. 

The Week That Was–Feb 15 To Feb 19, 2021

Key indices ended with modest losses as investors booked profits after recent rally. Rising global and local bond yields impacted sentiment. The up move was triggered by a range of positive developments, including a high-spending union budget, strong corporate earnings, robust foreign fund flows and progress on COVID-19 vaccinations. 

The Sensex settled below the key 51,000 level while the Nifty ended below the psychological 15,000 mark. Both these indices retreated after scaling record highs. However, the broader markets that are BSE Midcap index and the BSE Small cap Index, both, ended in the green last week.

In the week ended Friday, February 19, 2021, the Sensex dropped 654.54 points or 1.27% to settle at 50,889.76. The Nifty 50 index shed 181.55 points or 1.20% to settle at 14,981.75. The BSE Midcap index rose 124.49 or 0.63% to settle at 20,035.52. The BSE Small cap index added 241.36 points or 1.23% to settle at 19,863.41.

Global Markets

Asian share markets inched higher to day as expectations for faster economic growth and inflation globally batter bonds and boost commodities, though rising real yields also make equity valuations look more stretched in comparison. 

MSCI’s broadest index of Asia-Pacific shares outside Japan added 0.1%, after easing from a record top late last week as the jump in US bond yields unsettled investors.

Japan’s Nikkei recouped 1.0% and South Korea 0.4%, while E-Mini futures for the S&P 500 were a fraction firmer.

Oil, Rupee & FIIs 

Crude Oil: Oil prices have gone along for the ride, aided by tightening supplies and freezing weather, giving Brent gains of 21% for the year so far. Early Monday, Brent crude futures were up 43 cents at $63.34 a barrel, while US crude added 11 cents to $59.35.

Indian Rupee: Buoyed by foreign fund inflow and weaker US dollar, the Indian rupee is trading at its highest level in almost a year. On Friday the rupee closed flat at 72.65 against the greenback, as foreign funds continued to pump monies into Indian markets. 

FPIs: On Friday, foreign institutional investors (FIIs) net bought shares worth Rs 118.75 crore, while domestic institutional investors (DIIs) net sold shares worth Rs 1,174.98 crore in the Indian equity market.

Foreign portfolio investors (FPIs) invested Rs 24,965 crore in Indian markets in February so far. According to depositories’ data, FPIs pumped in Rs 24,204 crore into equities and Rs 761 crore in the debt segment, taking the total net investment to Rs 24,965 crore during February 1-19.

Week Ahead

Trading could be volatile this week as traders roll over positions in the F&O segment from the near month January series to February series. The February 2021 F&O contracts will expire on Thursday.

Trend in global markets, macro data, movement of rupee against the dollar, Brent crude oil price movement and investments by foreign portfolio investors (FPI) and domestic institutional investors (DII) will be watched.

On the macro front, India's gross domestic product (GDP) for the fourth quarter will be released on February 26, 2021. India's infrastructure output data for January will be unveiled on February 26, 2021. 

Global cues will continue to be in focus as resurgence in virus cases around the world, leads to more restrictions and more pressure on economic recovery. Updates related to COVID-19 will be closely watched. Also, on the radar will be news on Covid vaccine development. From here on the pace of the improvement of economic indicators along with outcomes of a possible vaccine or cure for COVID-19 would determine the movement of the market.

China will announce Loan Prime Rate for 1 year and 5 years today. The United States Durable Goods Orders for January will be declared on February 25, 2021.

Sources: Various publications

Disclaimer: The information provided herein is based on publicly available information and other sources believed to be reliable, but involve uncertainties that could cause actual events to differ materially from those expressed or implied in such statements. The document is given for general and information purpose and is neither an investment advice nor an offer to sell nor a solicitation. While due care has been exercised while preparing this document, we do not warrant the completeness or accuracy of the information. We will not accept any liability arising from the use of this material. The recipient of this material should rely on their investigations and take their own professional advice.

Follow, Like, subscribe and share

"Your Trust, Our Financial Expertise."

Infyture, Investment For Your Future

Email: infyture@gmail.com

Website: http://infyture.wordpress.com

Facebook Page: https://www.facebook.com/infyture4future/

Youtube:https://www.youtube.com/channel/UCjOxVGTKQiK5O0mdcuMBCdw?view_as=subscriber

Blogger: https://infyture.blogspot.com/

WhatsApp: https://wa.me/message/SXE3AQCBR3O4B1

Telegram: https://t.me/infyture

Goal Based Planning || Equity Tip || Demat Account || Mutual Fund Investment || Life Insurance || General & Health Insurance || PMS & mini PMS || Retirement Planning || NPS Enrollment

Wednesday, February 10, 2021

IPO Analysis : Nureca Limited IPO

IPO Analysis : Nureca Limited IPO

Nureca Limited is a healthcare and wellness products distributor which got incorporated in 2016. The company aims to offer the best quality, durable, and innovative tools to customers to monitor chronic diseases to improve their lifestyle.


The firm has a well-diversified product portfolio including Chronic Device Products, Orthopedic products, Mother and Child products, Nutrition Supplements, and Lifestyle products to meet the Indian healthcare market requirements. It is the first digital company to sell such products through its website and other online partners i.e. e-commerce players, retailers, and distributors.

Let's discuss the products portfolio of Nureca in a bit detail:

Chronic Device Products – including products such as blood pressure monitors, pulse oximeters, thermometers, nebulizers, self-monitoring glucose devices, humidifiers, and steamers.

Orthopedic Products – including rehabilitation products such as wheelchairs, walkers, lumbar and tailbone supports, and physiotherapy electric massagers.

Mother and Child Products – which includes products such as breast pumps, bottle sterilizers, bottle warmers, car seats, and baby carrycots.

Nutrition Supplements – including products such as fish oil, multivitamins, probiotics, biotin, apple cider, and vinegar.

Lifestyle Products – including products such as smart scales, aroma diffusers, and fitness trackers.

A few products sold by the Company:

    Dr. Trust Wheelchair.
    Dr. Trust Walker.
    Dr. Trust Walker with wheels.
    Dr. Physio Full Body Massager.
    Dr. Trust Fish oil.
    Dr. Trust Multivitamins.
    Dr. Trust Balance Scale.
    Dr. Trust Fitness Tracker Smart band.

Company’s Distribution Network:

Nureca is a digital first company where in company sells the products through online channels partners such as e-commerce players, distributors and retailer.Further, company also sell its products through company’s own website drtrust.in

Currently, 95% of revenues for the Company comes through digital channels (e-Commerce).

Tie up with Croma:

To expand the business footprint, Nureca, in October 2019, joined hands with Croma, India’s first omni-channel electronics retailer from the Tata Group, to emerge as the very first company to sell healthcare and wellness products through Croma stores.

As part of this tie-up, Nureca will sell products from its Dr Trust and Dr Physio brands at 30 Croma stores across the country.

Competition in the Business:

Nureca competes with local and global companies operating in India. The market is extremely fragmented with over fifty players, most of them Indian, with mostly generic products, showcasing no significant competitive advantage in terms of innovation or differentiation.

There are numerous other players in the market, like Dr Morepen, Health Sense, Agaro, Lifelong, Omron, Philips, Johnson and Johnson, Roche, Bayer

Positives for the Company:

Growth in Home Health Segment.The Home Health Market in India and neighbouring countries is pegged at Rs.20,757.0 crore in 2019 and is expected to grow to Rs.38,920.7 crore by 2025 at a CAGR 11.0%. The growth is driven by rising awareness of Health and wellness, increasing spending power, growing burden of chronic diseases, and the need for Healthcare stakeholders to reduce healthcare costs.

Marketing & Distribution of Products: Company markets and sells the products across India through company’s own website i.e. Dr trust.in and third party e-commerce platforms, distributors and retailers and manage the sales and marketing activities through our Corporate Office. Company believes that this distribution network ensures that the products are easily available in almost any part of India. In addition to leveraging and engaging the distribution network for marketing initiatives, company also undertake direct promotional initiatives like advertising the products through digital marketing.

Reputed Brand with Constant Innovation: Company’s brands i.e Dr. Trust, Dr. Physio and Trumom have built a reputation of introducing innovative products that appeal to Indian customers. Company combines the technical expertise with an understanding of the Indian home healthcare market developed through market feedback and extensive interaction with the vendors. Through these efforts, company seeks to be the first to introduce innovative products in the market with unique functionalities that create new demand.
    
For example, Nureca has launched BP monitors which can be connected to a mobile phone through bluetooth or our own application i.e. Dr. Trust BP Connect App for remote monitoring of the patient.

Other Important Dates and Facts: 



Verdict: Seeing the company structure and future prospects, I think one should apply in this IPO. Since company's main focus is on e Commerce and digital marketing, hence their will not be any question on sustainability of the company. 
Seeing high action in secondary market, one can expect listing gains also. 

Sources: Various publications

Disclaimer: The information provided herein is based on publicly available information and other sources believed to be reliable, but involve uncertainties that could cause actual events to differ materially from those expressed or implied in such statements. The document is given for general and information purpose and is neither an investment advice nor an offer to sell nor a solicitation. While due care has been exercised while preparing this document, we do not warrant the completeness or accuracy of the information. We will not accept any liability arising from the use of this material. The recipient of this material should rely on their investigations and take their own professional advice.

Follow, Like, subscribe and share

"Your Trust, Our Financial Expertise."

Infyture, Investment For Your Future

Email: infyture@gmail.com

Website: http://infyture.wordpress.com

Facebook Page: https://www.facebook.com/infyture4future/

Youtube:https://www.youtube.com/channel/UCjOxVGTKQiK5O0mdcuMBCdw?view_as=subscriber

Blogger: https://infyture.blogspot.com/

WhatsApp: https://wa.me/message/SXE3AQCBR3O4B1
Telegram:
https://t.me/infyture

Goal Based Planning || Equity Tip || Demat Account || Mutual Fund Investment || Life Insurance || General & Health Insurance || PMS & mini PMS || Retirement Planning || NPS Enrollment

Disable copy